Research shows that type 2 diabetes causes a critical healing protein called TSG-6 to nearly disappear from skin tissue, leading to excessive inflammation and dramatically slower wound healing. According to research reviewed by Gram, when scientists restored TSG-6 levels in diabetic mouse wounds, healing speed returned to normal and inflammation dropped significantly. This discovery identifies a specific cause of diabetic wound problems and suggests that TSG-6 protein therapy could become a future treatment to prevent serious foot infections in diabetic patients.

According to research reviewed by Gram, scientists discovered that people with type 2 diabetes have dangerously low levels of a healing protein called TSG-6 in their skin. This missing protein causes wounds to stay inflamed longer and heal much slower than normal. When researchers added this protein back to diabetic wounds in mice, healing returned to normal speed and inflammation dropped significantly. This finding could eventually lead to new treatments that help diabetic patients avoid serious foot wounds and infections that currently affect millions worldwide.

Key Statistics

A 2026 research study in mice found that type 2 diabetic animals had markedly reduced TSG-6 protein levels in their skin compared to healthy mice, and this reduction was associated with delayed wound closure and elevated pro-inflammatory markers including IL-6, TNF-alpha, and MIP-1-alpha.

When TSG-6 protein was reintroduced directly into diabetic mouse wounds, healing rates normalized to match healthy mice and inflammatory cytokine levels returned to normal ranges, demonstrating that TSG-6 deficiency is a direct cause of slow diabetic wound healing.

The 2026 study used two different diabetes models in mice (genetic and diet-induced) and found the same pattern of low TSG-6 and delayed healing in both, suggesting that TSG-6 deficiency is a fundamental mechanism of diabetic wound complications regardless of how the disease develops.

The Quick Take

  • What they studied: Why wounds heal slowly in people with type 2 diabetes, focusing on a specific protein called TSG-6 that helps control inflammation
  • Who participated: Laboratory mice with type 2 diabetes created two ways: genetically diabetic mice and mice fed a high-fat diet plus given a chemical to trigger diabetes, mimicking how the disease develops in humans
  • Key finding: Diabetic mice had much lower levels of TSG-6 protein in their skin compared to healthy mice, and this missing protein caused wounds to stay inflamed and heal slowly. When scientists added TSG-6 back to the wounds, healing speed returned to normal
  • What it means for you: This research suggests that a future treatment adding TSG-6 protein to diabetic wounds could dramatically speed healing and prevent serious foot infections. However, this is early-stage research in mice, so human treatments are still years away

The Research Details

Researchers created two different types of diabetic mice to test their theory. The first group had a genetic mutation that naturally causes diabetes, similar to how some people inherit the condition. The second group ate a high-fat diet and received a chemical injection to trigger diabetes, which mimics how most people develop type 2 diabetes through lifestyle factors. Both groups developed sustained high blood sugar, just like diabetic patients. The scientists then created small wounds on the mice’s skin and carefully tracked how fast they healed, measuring wound size over time. They also analyzed the skin tissue to measure levels of TSG-6 protein and inflammation markers.

The researchers compared diabetic mice to healthy mice without diabetes to see the differences. They measured specific inflammation chemicals in the wounds, including IL-6, TNF-alpha, and MIP-1-alpha, which are the same inflammatory markers that cause problems in human diabetic wounds. They also counted immune cells called macrophages that help clean up damaged tissue and fight infection. Finally, they tested whether adding TSG-6 protein directly to diabetic wounds would reverse the healing problems.

This approach allowed scientists to understand both what goes wrong in diabetic wounds and whether fixing the TSG-6 problem could restore normal healing. Using two different diabetes models strengthened their findings by showing the same pattern occurs whether diabetes is genetic or diet-caused.

This research design is important because it identifies a specific cause of slow wound healing in diabetes rather than just describing the problem. By testing whether adding TSG-6 fixes the issue, researchers demonstrated that this protein is not just associated with slow healing but actually causes it. This is the critical step needed before developing new treatments for patients

This study was conducted by experienced researchers using established laboratory methods and two different diabetes models, which strengthens confidence in the findings. The research was published on bioRxiv, a preprint server where scientists share work before formal peer review. This means the findings have not yet been reviewed by independent experts, so readers should view this as preliminary evidence rather than final proof. The study used mice rather than humans, so results may not directly translate to how treatments would work in people. However, mouse models are standard in early-stage research and often predict human outcomes reasonably well

What the Results Show

Both types of diabetic mice showed the same pattern: their wounds healed much more slowly than healthy mice, and their skin contained significantly lower levels of TSG-6 protein. This low TSG-6 was present even before the wound was created, suggesting that diabetes itself causes the protein to disappear from skin tissue. The diabetic wounds also showed excessive inflammation with high levels of pro-inflammatory chemicals (IL-6, TNF-alpha, and MIP-1-alpha) that normally trigger healing but become harmful when they stay elevated too long.

When researchers added TSG-6 protein directly into the diabetic wounds, something remarkable happened: the wounds healed at normal speed, matching the healing rate of healthy mice. The inflammation markers dropped to normal levels, and immune cells called macrophages accumulated in the wound area at healthy levels. This demonstrated that TSG-6 is not just missing in diabetic wounds but is actively needed for normal healing to occur.

The research shows that TSG-6 works by controlling inflammation through a specific mechanism: it binds to inflammatory molecules and prevents them from activating immune cells excessively. In diabetes, without enough TSG-6, these inflammatory molecules run wild, creating a hostile environment where healing cells cannot work properly. The protein essentially acts as a brake on inflammation, and diabetes removes that brake.

The study found that TSG-6 levels were low throughout the entire skin tissue of diabetic mice, not just at wound sites. This suggests that diabetes causes a widespread problem with TSG-6 production rather than a localized issue. The research also showed that macrophage immune cells accumulated properly when TSG-6 was restored, indicating that this protein helps recruit the right immune cells to wounds. Additionally, the findings were consistent across both genetic and diet-induced diabetes models, suggesting the mechanism is fundamental to how diabetes affects healing regardless of how the disease develops

Previous research had shown that mice completely lacking TSG-6 have severe wound healing problems and excessive skin inflammation, but this study is the first to demonstrate that type 2 diabetes specifically reduces TSG-6 levels and that this reduction contributes to slow healing. The findings fit with existing knowledge that diabetes causes excessive inflammation that interferes with healing, but they identify TSG-6 as a specific missing piece of that puzzle. This research builds on decades of work showing that controlling inflammation can improve diabetic wound healing

This study used mice rather than humans, so results may not directly apply to diabetic patients. The sample size of mice is not specified in the abstract, making it unclear how many animals were tested. The research was conducted in a laboratory setting with controlled conditions, whereas real diabetic wounds occur in complex human bodies with many other factors affecting healing. The study did not test whether TSG-6 treatment would work in mice with other complications of diabetes, such as nerve damage or blood vessel problems. Additionally, the research does not explain why diabetes causes TSG-6 levels to drop in the first place, which would be important for developing preventive treatments

The Bottom Line

This research is too early to recommend any changes to current diabetic wound care. Current best practices including blood sugar control, wound cleaning, and proper dressing should continue. However, this study provides strong preliminary evidence that TSG-6 protein therapy could become a future treatment option for diabetic wounds. People with type 2 diabetes should discuss wound care strategies with their doctors and watch for future clinical trials testing TSG-6 treatments. Confidence level: This is early-stage research in mice, so confidence in human application is moderate to low at this stage

People with type 2 diabetes who have experienced slow-healing wounds or foot ulcers should find this research particularly relevant, as it may lead to treatments specifically designed for their condition. Healthcare providers treating diabetic wounds should monitor for future clinical trials. People at risk for type 2 diabetes may benefit from understanding that inflammation plays a key role in diabetic complications, reinforcing the importance of prevention through diet and exercise. This research is less immediately relevant to people without diabetes or those with type 1 diabetes, though the mechanisms may partially overlap

If TSG-6 protein therapy moves forward, it would typically require 3 to 5 years of additional laboratory testing, followed by 5 to 10 years of human clinical trials before becoming available as a treatment. Realistic timeline for patient access is 8 to 15 years from now, assuming the research continues to show promise

Frequently Asked Questions

Why do diabetics have trouble healing wounds?

Type 2 diabetes causes a protein called TSG-6 to drop dramatically in skin tissue. Without enough TSG-6, inflammation spirals out of control, creating an environment where healing cells cannot work properly. This excessive inflammation is the primary reason diabetic wounds heal slowly

Can TSG-6 protein be used to treat diabetic foot ulcers?

This 2026 mouse study shows that adding TSG-6 protein directly to diabetic wounds restores normal healing speed and reduces inflammation. However, this is early-stage research, and human clinical trials would be needed before TSG-6 therapy becomes available as a treatment, likely 8 to 15 years away

What can diabetics do now to heal wounds faster?

Current best practices include tight blood sugar control, keeping wounds clean and properly dressed, avoiding pressure on the wound, and seeking immediate medical attention for signs of infection. These approaches address the underlying inflammation problem while researchers develop new treatments like TSG-6 therapy

Is this research applicable to type 1 diabetes?

This study specifically examined type 2 diabetes in mice. Type 1 diabetes involves different immune mechanisms, so TSG-6 deficiency may or may not play the same role. Additional research would be needed to determine if TSG-6 therapy could help type 1 diabetic wound healing

How does TSG-6 protein actually help wounds heal?

TSG-6 acts as a brake on inflammation by binding to inflammatory molecules and preventing them from over-activating immune cells. In diabetes, without enough TSG-6, inflammatory chemicals run unchecked, creating a hostile environment that prevents healing cells from working normally

Want to Apply This Research?

  • Users with diabetic wounds can photograph wounds weekly from the same angle and distance, measuring visible wound size in millimeters using a ruler in the photo. Track healing progress over 2 to 4 weeks to identify whether wounds are improving at expected rates or showing delayed healing that warrants medical attention
  • Set daily reminders to check blood sugar levels and log results in the app, since this research emphasizes that controlling blood sugar is fundamental to wound healing. Users can also track wound care routines including cleaning, dressing changes, and any signs of infection, creating accountability for the daily habits that support healing
  • Create a long-term wound healing dashboard that tracks healing rate over months, correlating it with blood sugar control metrics. Users can identify patterns showing whether better blood sugar management correlates with faster healing, providing personalized evidence of the connection between glucose control and wound recovery

This research is preliminary and has not yet undergone formal peer review. The study was conducted in mice, and results may not directly apply to humans. This information is for educational purposes only and should not replace professional medical advice. People with type 2 diabetes should continue following their doctor’s current wound care recommendations and blood sugar management strategies. Do not attempt to self-treat diabetic wounds or delay seeking medical care based on this research. Anyone with a diabetic wound or foot ulcer should contact their healthcare provider immediately for proper evaluation and treatment

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: Abnormally low expression of tumor necrosis factor stimulated gene 6 (TSG-6) in obese type 2 diabetic mice contributes to altered inflammation and delayed cutaneous wound healing. , bioRxiv : the preprint server for biology (2026). PubMed 42818053 | DOI
Topics
type 2 diabetes wound healing TSG-6 protein inflammation diabetic foot ulcers slow wound healing diabetes inflammatory cytokines diabetic complications wound care diabetes TSG-6 therapy